Mobile

A randomized phase III, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of everolimus (RAD001) in adult patients with advanced Hepatocellular Carcinoma after ...

Update Il y a 5 ans
Reference: EUCTR2009-010196-25

A randomized phase III, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of everolimus (RAD001) in adult patients with advanced Hepatocellular Carcinoma after failure of sorafenib treatment The EVOLVE-1 Study

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The primary objective of this study is to compare overall survival between the combination treatment of everolimus plus BSC to placebo plus BSC in patients with advanced HCC whose disease progressed while on or after sorafenib treatment or who are intolerant to sorafenib.

Inclusion criteria

  • Hepatocellular carcinoma non-resectable

Links